Our latest news on Magmaris RMS
20
September
2022
|
15:41
Europe/Amsterdam
BIOSOLVE-IV Full-Cohort Two-Year Data Confirm Excellent Safety and Efficacy Profile of Magmaris Resorbable Magnesium Scaffold
Magmaris Scaffold Performs Well in Real World Settings Even in More Complex Patient Groups
BIOTRONIK announced the presentation of new full-cohort 2-year BIOSOLVE-IV data. In a poster session at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2022, principal investigator …
17
May
2022
|
09:32
Europe/Amsterdam
EuroPCR: Magmaris Resorbable Magnesium Scaffold Confirms High Safety Profile at 3 Years With BIOSOLVE-IV Data
Two poster sessions at EuroPCR focus on Magmaris’ safety profile for the first cohort after three years and the full cohort subgroup analysis at one-year follow-up
Two posters presented at the EuroPCR provided new insights into the safety profile of BIOTRONIK's Magmaris Resorbable Magnesium Scaffold (RMS). BIOSOLVE-IV study investigator Prof. Dr. Jan Torzewski, …
08
November
2021
|
09:09
Europe/Amsterdam
Superiority of BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) in Scaffold Thrombosis shown versus Abbott’s Absorb Bioresorbable Vascular Scaffold in Largest Patient Cohort to Date
BIOSOLVE-IV Registry one-year follow up data, analyzing 2,066 patients showed Superiority of BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) versus Abbott’s Absorb Bioresorbable Vascular Scaffold in Scaffold Thrombosis*
Superiority of the Magmaris sirolimus-eluting bioresorbable magnesium scaffold with regard to probable or definite scaffold thrombosis compared to a historical control group of Absorb scaffold data …
18
May
2021
|
09:00
Europe/Amsterdam
Real-World Data Confirms Long-Term Safety and Efficacy of BIOTRONIK’s Bioresorbable Scaffold
BIOSOLVE-IV registry two-year data show low event rates for the Magmaris RMS, comparable to second generation drug-eluting stents
New, long-term follow-up data from the BIOSOLVE-IV real-world registry strengthens the clinical evidence for BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) as a therapy option for patients …
15
November
2020
|
17:56
Europe/Amsterdam
Future of Resorbable Scaffolds Looks Rosier
As more data comes in, there’s plenty of reasons to be optimistic about scaffolds
In their short time on the market, bioresorbable vascular scaffolds have generated plenty of discussion within interventional cardiology. According to the authors of “Fading Away or Hope for the …
30
September
2019
|
00:00
Europe/Amsterdam
TCT 2019: Real-World Registry Data Confirm Safety of Resorbable Scaffold Technology
Magmaris Scaffold Shows Low Complication Rates, Benefiting Patients with Both Stable and Unstable Coronary Artery Disease
Full cohort data from the BIOSOLVE-IV registry strengthen the clinical evidence for BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery …